摘要
本文观察了化疗药物联合ｒＩＬ－２对２８例肺癌及肝癌患者的生物化学治疗效果并与１４例单纯化疗患者（对照组）进行了对比。结果显示：实验组有效率（ＣＲ＋ＰＲ）分别为肝癌３１％、肺癌４２％，合并有效率（ＣＲ＋ＰＲ）为３６％，均显著高于对照组（１３％、１７％、１４％，Ｐ＜０．０１）。主观症状改善及生存率方面实验组优于对照组Ｐ＜０．０５。本研究结果提示，化疗联合ｒＩＬ－２对晚期肝癌及肺癌有较明显疗效。
The effectiveness of the combined use of chemotherapy and rIL2 were evaluated in 28 advanced patients with primary liver cancer and non small cell lung cancer,and were also compared with the controlsThe results showed that the effective rate (CR+PR)in studyed groups were as follows respectly:31%(primary liver cancer),42%(PNSCLC),36%(total CR+PR),which were statiscally higher than those of controls respectly(13%,17%,14%,P<001)The rate which the KS(karnofsky)were improved in studyed groups were also better than those of controls(43%vs21%,P<005)The rates of life in studyed groups were higher than that of controls,the other side effects was not different significantly between the two groups except feverThe results indicated that Biochemotherapy are very effective in advanced patients with primary liver cancer and NSCLC and better than those of controls
出处
《广西医学》
CAS
1997年第6期951-954,共4页
Guangxi Medical Journal
